Established in 2002 by Mark E. Rubenstein and the Rubenstein family in memory of Barbara B. Rubenstein

BARBARA B. RUBENSTEIN, who succumbed to breast cancer in 2001, was a charter member of the Hopkins Kimmel Cancer Center Advisory Council and a devoted friend of the center's director, Martin Abeloff, MD. A tireless advocate for translational research and the concept of rapidly directing knowledge gained in the laboratory to the clinic and patients, Mrs. Rubenstein challenged the faculty to consider new ways of approaching research discovery. Family and friends are also establishing the Barbara B. Rubenstein Scholar Award at Hopkins to support an outstanding young investigator in breast cancer research. The Philadelphia Art Museum, where she had served as a trustee and chair of the European Decorative Arts Committee, named a gallery in her honor.


MARK E. RUBENSTEIN, Engr 1962, 1967 (MSE), a member of the Johns Hopkins Medicine Board and an emeritus trustee of Johns Hopkins University, is chairman and founder of The Rubenstein Company in Philadelphia, a firm involved in acquisitions, development, construction, leasing, management, and financing of substantial real estate projects. Mr. Rubenstein received from the Johns Hopkins Alumni Association the Heritage Award in 1996 and the Distinguished Alumni Award in 1999. He participates on the Whiting School of Engineering National Advisory Council.


SARASWATI SUKUMAR, the inaugural Barbara B. Rubenstein Professor of Oncology, is an internationally recognized expert in the area of molecular and cellular biology of breast cancer. After receiving her PhD in India, she pursued postdoctoral training as a fellow at the National Cancer Institute, then joined the faculty at Salk Institute in 1987. She came to Hopkins in 1994 and is currently co-director of the Breast Cancer Program. She holds appointments in oncology and pathology at the School of Medicine and in the School of Nursing. Dr. Sukumar has published numerous scientific papers on the molecular mechanisms underlying breast cancer, and is currently testing early detection methods for breast cancer.